LCM
ADMA icon

Legato Capital Management’s ADMA Biologics ADMA Stock Holding History

Legato Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,895
Closed -$564K – 731
2025
Q4 		$564K Buy
30,895
+1,374
+5% +$23.2K 0.05% 512
2025
Q3 		$433K Sell
29,521
-103,411
-78% -$1.77M 0.05% 458
2025
Q2 		$2.42M Buy
132,932
+33,014
+33% +$673K 0.29% 85
2025
Q1 		$1.98M Buy
99,918
+56,633
+131% +$979K 0.27% 100
2024
Q4 		$742K Sell
43,285
-17,347
-29% -$326K 0.1% 367
2024
Q3 		$1.21M Buy
+60,632
New +$943K 0.15% 246

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Legato Capital Management's ADMA Position: Q1 2026 in Review

Legato Capital Management sold out of ADMA Biologics (ADMA) in Q1 2026, closing a stake of 30,895 shares — an estimated $564K sold.

Legato Capital Management first reported a position in ADMA in Q3 2024 and held it in 6 quarters. The position peaked at $2.42M in Q2 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Legato Capital Management reported no remaining ADMA Biologics position as of Q1 2026 after selling out during the quarter.
  • Legato Capital Management sold 30,895 ADMA Biologics shares in Q1 2026, an estimated $564K.
  • Legato Capital Management first reported a position in ADMA Biologics in Q3 2024 and held it in 6 quarters.
  • Legato Capital Management's ADMA Biologics position peaked at $2.42M in Q2 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.